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Abstract 
Glycogen-rich clear cell (GRCC) is a rare subtype of breast carcinoma characterized by 
carcinoma cells containing an optically clear cytoplasm and intracytoplasmic glycogen. We 
present the case of a 55-year-old woman with a palpable mass in the right breast and clinical 
signs of locally advanced breast cancer (LABC). The diagnosis of GRCC carcinoma was based 
on certain histopathological characteristics of the tumor and immunohistochemical analysis. 
To our knowledge, this is the first case of GRCC LABC with intratumoral calcifications. There 
is no evidence of recurrence or metastatic disease after 14 months’ follow-up. 
 
Introduction 
Glycogen-rich clear cell (GRCC) breast carcinoma is a rare neoplasm of the breast, 
first described by Hull et al. [1] in 1981, and characterized by carcinoma cells 
containing an optically clear cytoplasm and intracytoplasmic glycogen [2–10]. 
We present a case of GRCC locally advanced breast cancer (LABC) with intratumoral 
calcifications. To our knowledge, such a presentation of GRCC breast carcinoma has not 
been reported previously. Case Rep Oncol 2011;4:452–457 
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Case Report 
A 55-year-old female patient presented with a 4-month history of a mass in the right breast. 
Physical examination revealed erythema, hyperemia and tenderness to the touch of the right breast. A 
palpable mass, hard in consistency and measuring about 15 cm, was present in the right superior and 
inferior lateral quadrants. Mammography showed a round, high-density mass with almost regular but 
partially irregular margins, measuring approximately 10 cm with calcifications suspicious of 
malignancy, and skin thickening (fig. 1). Ultrasound examination of the right breast showed a solid, 
heterogeneous mass. 
Ultrasound-guided core needle biopsy (CNB) of the mass was performed. Microscopic examination 
of the CNB showed extensive infiltration by a malignant epithelial-type neoplasm, consisting of solid 
nidi of atypical cells with ample clear cytoplasm, which had distinct and well-defined borders, was 
optically empty and ‘vegetaloid’ in appearance (fig. 2), interspersed with small areas of respected 
mammary parenchyma and extensive areas of necrosis. The nuclei were small and round with 
hyperchromasia and moderate pleomorphism, and showed a moderate mitotic index. No areas of 
carcinoma in situ were observed. 
On histochemical examination, the neoplastic cells were intensely positive for periodic acid-Schiff 
(PAS) staining (fig. 3), cytokeratin AE1/AE3, cytokeratin 7 and E-cadherin, and negative for PAS 
diastase, HER2, and estrogen and progesterone receptors. A total absence of basal cells was shown by 
staining with P-63. The histopathological diagnosis was GRCC-infiltrating ductal carcinoma. 
The patient received neoadjuvant therapy consisting of epirubicin 75 mg/m2 and docetaxel 75 
mg/m2 every 3 weeks for 3 cycles. The clinical response to the chemotherapy treatment was partial. 
Moreover, the patient presented with a skin ulcer in the area corresponding to the tumor. A modified 
radical mastectomy with axillary lymph node dissection was performed. 
Macroscopic examination of the modified radical mastectomy specimen showed a skin ulcer, 
below which was a necrotic-looking tumor measuring 7 × 7 × 4 cm. Microscopic examination showed 
a neoplasm made up of solid nidi of atypical cells with clear cytoplasm and the same histopathological 
characteristics as described for the CNB. Inside the neoplasm we observed extensive areas of necrosis, 
as well as fibrosis, acute and chronic inflammatory reactions with the presence of spumous 
histiocytes, multinucleate giant cells and multiple foci of calcifications located in the midst of the 
necrotic areas (fig. 4). The pathological diagnosis of GRCC carcinoma, established by CNB, was 
confirmed. The pathological tumor response after treatment (Miller and Payne system) [11] was stage 
G2 with a discrete reduction in infiltrating tumor cellularity of less than 30% of the tumor mass. 
Twelve of the axillary lymph nodes removed were histologically tumor-free. Pathology revealed a 
T4N0M0 GRCC carcinoma. 
The patient was later submitted for chemotherapy (3 cycles of 75 mg/m2 epirubicin and 
docetaxel) followed by radiotherapy of the chest wall and lymph nodes within the axillary and 
supraclavicular regions (50 Gy). Diagnostic work-up (bone scintigraphy, thoracic, abdominal and 
pelvic CT scans) revealed no local or distant metastases. Fourteen months after surgery, the patient 
remains asymptomatic and disease-free. 
Discussion 
GRCC breast carcinoma is a rare neoplasm of the breast, with an incidence of 
between 1.4 and 3% of all breast cancers [2, 4, 7]. This tumor has particular 
morphological characteristics that distinguish it from other breast tumors, although it 
does share other characteristics with clear cell carcinoma of the lung, endometrium, 
cervix, ovary, kidneys and salivary glands [5]. The cells of GRCC carcinoma contain 
clear polygonal cytoplasm, round or oval hyperchromatic nuclei and prominent 
nucleoli. The cytoplasm contains abundant granules of hydrosoluble glycogen, which 
can be extracted during processing of the samples, giving it an ample, vacuolated Case Rep Oncol 2011;4:452–457 
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appearance. Furthermore, it contains PAS-positive material with a weak reaction to 
diastase [2, 3]. 
Fewer than 100 instances of GRCC carcinoma of the breast have been described 
since the first case was reported in 1981 [1–10]. Patient age varies from 35 to 78 years, 
and tumor size ranges from 2 to 5 cm, with the largest lesion found to be 10 cm on 
clinical examination [5, 9]. In our case, the size of the tumor on physical examination 
was 15 cm. Furthermore, clinical signs of LABC have been observed previously [12]. 
Therefore, the case presented here is the most voluminous GRCC carcinoma reported in 
the literature. Intratumoral calcifications seen on mammography were also observed in 
the present case, which is extremely rare. 
The differential diagnosis includes breast carcinomas with ample cytoplasm such as 
lipid-rich clear cell carcinoma, signet ring cell carcinoma, other secretory subtypes of 
ductal or lobular carcinoma and metastatic clear cell renal carcinoma [5, 6, 10]. There 
are various histological patterns of GRCC carcinoma (well-differentiated tubular, 
papillary and solid), which may or may not be associated with an intraductal carcinoma 
component [6–9]. Hormone-receptor analysis showed that approximately 50% of 
tumors were estrogen receptor-positive, but all the lesions studied were negative for 
progesterone receptors [1, 5]. In our patient, both estrogen and progesterone receptors 
were negative. 
As far as treatment is concerned, mastectomy and axillary dissection are usually 
performed, and more than 50% of patients studied had a metastatic tumor in the 
axillary lymph nodes [1, 4, 5, 9]. However, our patient received a combined treatment 
of chemotherapy, surgery and radiation therapy, due to the characteristics of the tumor 
(LABC). The prognosis of this type of breast cancer is still a subject of controversy, 
although GRCC breast carcinoma generally tends to follow an aggressive clinical course 
[2, 3, 5, 7]. 
In conclusion, to our knowledge, this is the first case of GRCC LABC with 
intratumoral calcifications and should be added to the differential diagnosis of breast 
carcinomas. Our T4N0M0-staged patient is disease-free 14 months after surgery. 
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Fig. 1. Craniocaudal mammogram showing a mass with calcifications (black arrows) and skin 
thickening (white arrows). 
 
 
 
Fig. 2. Photomicrograph of the tumor (H&E; ×200). The tumor cells show ample clear cytoplasm with 
well-defined limits and a ‘vegetaloid’ appearance. 
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Fig. 3. Positive (PAS; ×400). PAS reactivity is strong. 
 
 
 
Fig. 4. Photomicrograph of the tumor (H&E; ×100). Abundant calcifications and inflammatory 
infiltrate with multinucleate giant cells in the midst of the tumor necrosis. 
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